Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Nov;213(5):729.e1-9.
doi: 10.1016/j.ajog.2015.04.032. Epub 2015 Apr 30.

The effect of hydroxyquinoline-based gel on pessary-associated bacterial vaginosis: a multicenter randomized controlled trial

Kate V Meriwether  1 , Rebecca G Rogers  2 , Ellen Craig  2 , Sean D Peterson  3 , Robert E Gutman  4 , Cheryl B Iglesia  4
Affiliations
Randomized Controlled Trial

The effect of hydroxyquinoline-based gel on pessary-associated bacterial vaginosis: a multicenter randomized controlled trial

Kate V Meriwether et al. Am J Obstet Gynecol. 2015 Nov.

Abstract

Objective: Pessaries are important options for women with pelvic floor disorders, but many pessary users experience bacterial vaginosis (BV). The aim of this study was to evaluate the effect of TrimoSan gel (Milex Pessaries, Cooper Surgical, Trumbull, CT) on BV prevalence among pessary users.

Study design: Women presenting for a pessary fitting completed questionnaires on vaginal symptoms and hormone therapy use and underwent a BV BLUE test and slide collection for BV analysis by Nugent's criteria. Following pessary fitting, women were randomized to either standard pessary care with the use of TrimoSan placed vaginally twice weekly or to standard pessary care without TrimoSan gel. Women returned 2 weeks and 3 months later for a repeat slide collection for Gram stain, BV BLUE testing, and completion of questionnaires on vaginal symptoms and desire to continue the pessary.

Results: There were 184 women randomized after successful fitting (92 to the TrimoSan group), and 147 (79%) presented for 3-month follow up. Mean age was 56 ± 16 years; patients were mostly white (57%) or Hispanic (23%), and 36% were using hormone therapy. The groups did not differ in the prevalence of BV by Nugent's criteria at 2 weeks (20% TrimoSan vs 26% no gel, P = .46) or 3 months (24% TrimoSan vs 23% no gel, P = .82), nor did they differ in BV by BV BLUE testing at 2 weeks (0% TrimoSan vs 4% no gel, P = .12) or 3 months (3% TrimoSan vs 0% no gel, P = .15). The prevalence of at least one vaginal symptom did not differ between groups at 2 weeks (44% TrimoSan vs 45% no gel, P = .98) or 3 months (42% TrimoSan vs 32% no gel, P = .30). The TrimoSan group was equally likely to want to continue their pessary use compared with the standard care group at 2 weeks (90% vs 86%, P = .64) and 3 months (63% vs 60%, P = .76).

Conclusion: TrimoSan gel in the first 3 months of pessary use does not decrease the prevalence of BV or vaginal symptoms and does not alter the likelihood of a woman desiring to continue pessary use.

Trial registration: ClinicalTrials.gov NCT01471457.

Keywords: TrimoSan; bacterial vaginosis; discharge; pessary; removal.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure Statement: RG Rogers is a Chair DSMB for the Transform trial sponsored by American Medical Systems and receives royalties from Up-to-Date and McGraw Hill. The remaining authors report no conflicts of interest.

Figures

Figure 1
Figure 1. Participant Flow Diagram
This figure demonstrates the flow of participants through the randomized trial design.
See this image and copyright information in PMC

References

    1. Wu JM, Vaughan CP, Goode PS, Redden DT, Burgio KL, Richter HE, Markland AD. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014 Jan;123(1):141–8. - PMC - PubMed
    1. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol. 1997;89(4):501. - PubMed
    1. Robert M, Schulz JA, Harvey MA, Urogynaecology Committee. Lovatsis D, Walter JE, Chou Q, Easton WA, Epp A, Farrell SA, Geoffrion R, Girouard L, Gupta CK, Harvey MA, Larochelle A, Maslow KD, Neustaeder G, Pascali D, Pierce M, Robert M, Ross S, Schachter J, Schulz JA, Senikas V, Wilkie DH. Technical update on pessary use. J Obstet Gynaecol Can. 2013 Jul;35(7):664–74. - PubMed
    1. Komesu YM, Rogers RG, Rode MA, Craig EC, Gallegos KA, Montoya AR, Swartz CD. Pelvic floor symptom changes in pessary users. Am J Obstet Gynecol. 2007 Dec;197(6):620.e1–6. - PMC - PubMed
    1. Komesu YM, Rogers RG, Rode MA, Craig EC, Schrader RM, Gallegos KA, Villareal B. Patient-selected goal attainment for pessary wearers: what is the clinical relevance? Am J Obstet Gynecol. 2008 May;198(5):577.e1–5. - PMC - PubMed

Publication types

Associated data